AN1 — Anagenics Share Price
0.000.00%
Last trade - 00:00Consumer DefensivesHighly SpeculativeMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -260.34% | ||
| Return on Equity | -135.49% | ||
| Operating Margin | -87.3% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 7.34 | 5.82 | 6.95 | 9.11 | 10.8 | n/a | n/a | 7.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Anagenics Limited is an Australia-based health and beauty-tech company that operates health wellness and beauty business servicing wholesale and retail customers through omnichannel, offering premium branded products. The Company operates through its holding entity, Anagenics Limited and its main operating subsidiary company BLC Cosmetics Pty Limited (BLC) being a distributor of prestige beauty cosmetics and beauty equipment. BLC is an importer and distributor of prestige international and local skin care and wellbeing brands, namely Thalgo, Comfort Zone, Priori and other premium brands. BLC services over 1,000 spas, clinics, salons, retail stores and online in Australia, New Zealand and the Pacific Islands. The Company's brands consist of evolis and Uspa. Evolis is an anti-ageing hair care collection focused on harnessing the scientific research to give customers' thicker and healthier hair.
Directors
- Bruce Gordon NEC
- Maria Halasz CEO
- Dominic Burg COO
- Teruko Fujii MDR
- Carolyn Heath GMG
- Matthew Dudek CTR
- Trish Frelan OTH
- Phillip Christopher NED
- Martin Cross NED
- Dennis Eck NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 8th, 2004
- Public Since
- December 9th, 2005
- Sector
- Personal & Household Products & Services
- Industry
- Consumer Defensives
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 461,320,360
- Address
- Suite 204, Level 2, 55 Clarence Street, SYDNEY, 2000
- Web
- https://anagenics.com/
- Phone
- +61 292216830
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for AN1
Similar to AN1
Academies Australasia
Australian Stock Exchange - SEATS
Advance Zinctek
Australian Stock Exchange - SEATS
AF Legal
Australian Stock Exchange - SEATS
Ama
Australian Stock Exchange - SEATS
Count
Australian Stock Exchange - SEATS
FAQ
What is the Anagenics share price?
As of Today at 19:14 UTC, shares in Anagenics are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Anagenics share price performed this year?
Shares in Anagenics last closed at AU$0.01 and the price had moved by -57.89% over the past 365 days. In terms of relative price strength the Anagenics share price has underperformed the ASX All Ordinaries Index by -59.63% over the past year.
What are the analyst and broker recommendations for Anagenics?
The overall consensus recommendation for Anagenics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Anagenics dividend yield?
Anagenics does not currently pay a dividend.
Does Anagenics pay a dividend?
Anagenics does not currently pay a dividend.
When does Anagenics next pay dividends?
Anagenics does not currently pay a dividend.
How do I buy Anagenics shares?
To buy shares in Anagenics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Anagenics?
As of the previous close price of AU$0.01, shares in Anagenics had a market capitalisation of .
Where are Anagenics shares listed?
Here are the trading details for Anagenics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AN1
What kind of share is Anagenics?
Based on an overall assessment of its quality, value and momentum Anagenics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Anagenics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Anagenics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Anagenics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -44.69%.
As of the last closing price of AU$0.01, shares in Anagenics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Anagenics PE Ratio?
The Anagenics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Anagenics?
Anagenics' management team is headed by:
- Bruce Gordon - NEC
- Maria Halasz - CEO
- Dominic Burg - COO
- Teruko Fujii - MDR
- Carolyn Heath - GMG
- Matthew Dudek - CTR
- Trish Frelan - OTH
- Phillip Christopher - NED
- Martin Cross - NED
- Dennis Eck - NED